| Table 5: Case-control genotype associations with prostate cancer by non-Black and Black men (adjusted for age). |
| | Variables of interest | Non–Black (South African Mixed and White) | Black (South African Black and Senegalese) | | Genotypes | OR (95% CI) | OR (95% CI) |
| | CYP3A4 (rs2740574) | | | | AA | 1.00 (ref) | 1.00 (ref) | | AG | 3.58 (2.44–5.24)** | 0.80 (0.35–1.82) | | GG | 5.16 (1.85–14.39) | 0.65 (0.41–1.02) | | AG/GG | 3.95 (2.72–5.75)** | 0.59 (0.26–1.31) |
| | CYP3A5 (rs776746) | | | | GG | 1.00 (ref) | 1.00 (ref) | | AG | 1.78 (1.23–2.58) | 1.06 (0.24–4.63) | | AA | 1.30 (1.00–1.69) | 1.08 (0.57–2.02) | | AG/AA | 1.75 (1.25–2.45) | 1.13 (0.32–3.98) |
| | SRD5A2 V89L (rs523349) | | | | GG | 1.00 (ref) | 1.00 (ref) | | CG | 0.68 (0.48–0.96) | 0.26 (0.11–0.61)* | | CC | 0.79 (0.52–1.20) | 0.67 (0.46–0.97)* | | CG/CC | 0.67 (0.48–0.94) | 0.38 (0.19–0.77)* |
| | SRD5A2 A49T (rs9282858) | | | | GG | 1.00 (ref) | 1.00 (ref) | | AG | 1.88 (1.30–2.73) | 1.40 (0.48–4.12) | | AA | — | — | | AG/AA | 1.88 (1.30–2.73) | 1.40 (0.48–4.12) |
|
|
—: too few/no genotypes to estimate ORs.
*
.
**
.
|